Display Settings:

Format

Send to:

Choose Destination

    Sex Transm Dis. 2007 Sep;34(9):718-25.

    HSV-2 serologic testing in an HMO population: uptake and psychosocial sequelae.

    Richards J, Scholes D, Caka S, Drolette L, Magaret AM, Yarbro P, Lafferty W, Crosby R, Diclemente R, Wald A.

    Department of Medicine, University of Washington, Seattle, WA, USA.

    OBJECTIVES: To prospectively measure the uptake of Herpes simplex virus Type 2 (HSV-2) testing and psychosocial response to a new serologic diagnosis of HSV-2 in a health maintenance organization (HMO) population. STUDY DESIGN: Randomly selected urban HMO enrollees were invited to be tested for HSV-2 antibody at a research clinic. Participants had blood drawn and completed demographic and psychosocial questionnaires. RESULTS: Of 3111 eligible enrollees contacted, 344 (11%) were tested. Eighty-seven (26%) tested HSV-2 seropositive, and 44 (51%) of these did not report a prior genital herpes diagnosis. Distress, measured by the total mood disturbance, was 6.5 points higher on average following a new genital herpes diagnosis relative to baseline (actual range = 109 points, P = 0.003) but not statistically different from HSV-2 negative or previously diagnosed participants. CONCLUSIONS: HMO enrollees unexpectedly testing HSV-2 positive showed short-term psychosocial distress that resolved during 6-month follow-up. Findings suggest that concerns about psychosocial burden should not deter voluntary serologic HSV-2 testing in primary care settings.

    PMID: 17471113 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read